- Conditions
- Hepatocellular Carcinoma
- Interventions
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- La Jolla, California • Los Angeles, California • Baltimore, Maryland + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,596
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Cancer
- Interventions
- bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer
- Interventions
- Tremelimumab, Durvalumab, Radiation
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
- Interventions
- PSMA/PRAME
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more
- Conditions
- Cancer of Liver, Pancreatic Cancer, Biliary Tract Cancer
- Interventions
- HPB Surgery
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Liver Cancer, Advanced Cancer
- Interventions
- Irinotecan, Bevacizumab, Oxaliplatin, Cetuximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
- Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 3
- States / cities
- Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colorectal Cancer Screening, Hepatitis C Virus
- Interventions
- MATCHES
- Behavioral
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Interventions
- Futibatinib, Pembrolizumab, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors
- Interventions
- Pasireotide Long Acting Release (LAR)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 2
- States / cities
- Stanford, California • Tampa, Florida
- Conditions
- Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
- Interventions
- OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests
- Device · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 754 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hepatic Impairment, Healthy Volunteers
- Interventions
- Bocidelpar
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
- Interventions
- Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
- Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- MTC-DOX for Injection
- Drug
- Lead sponsor
- FeRx
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 11
- States / cities
- Long Beach, California • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis
- Interventions
- Not listed
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Miwaukee, Wisconsin
- Conditions
- Neoplasms
- Interventions
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
- Conditions
- Liver Cancer
- Interventions
- Proton Beam Irradiation
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Metastatic Liver Cancer
- Interventions
- SIRT, capecitabine
- Radiation · Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Multiple Organ Failure, Health Care Quality, Access, and Evaluation, Intensive Care Units, Palliative Care, Health Services, Palliative Care, Patient Care, Lung Diseases, Cerebrovascular Disorders, Brain Injuries
- Interventions
- Facilitator-Based Intervention
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 977 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Patupilone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hepatocellular Carinoma
- Interventions
- JX-594 recombinant vaccina GM-CSF
- Biological
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas